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Abstract
The plasticity of adipose tissue (AT) is related to its angiogenic ability. Angiogenesis is a
multistep process which involves endothelial cell (EC) proliferation, migration, invasion
and finally tube formation. AT as a secretory organ produces adipokines, which contrib-
utes to the development of subclinical inflammation. The inflammation-related
adipokines deteriorate EC function and in consequence change the production of endo-
thelial mediators responsible for vascular homeostasis and angiogenesis, leading to
cardiovascular diseases (CVD) in obese patients. Additionally, the recent observation
suggests that AT is poorly oxygenated in obesity. Hypoxia limits the healthy expansion
of AT and stimulates a molecular response, enhancing nuclear factor kappa-B (NF-kB)
and hypoxia-inducible factor (HIF-1) expression. HIF-1α induction does not start a
normal angiogenic process but rather induces inflammatory response and fibrosis that
is strongly associated with insulin resistance (IR). It is believed that EC dysfunction in
obesity can be reduced by caloric restriction (CR). Moderate CR reflects a real-life
situation and could be optimal to achieve an EC improvement. It reduces adiposity
leading to pro-angiogenic, anti-inflammatory and—to a lesser extent—anti-oxidative
cellular effects, which not only preserves the healthy EC phenotype but also leads to an
improvement of AT remodeling and prevent systemic IR.
Keywords: obesity, angiogenesis, endothelial dysfunction, adipokines, caloric
restriction
1. Introduction
Obesity (adiposity) is a serious health problem, especially in well-developed countries. The
regional distribution of fat determines our health. Excessive accumulation of fat in the upper
body’s region (central obesity) is a stronger predictor of morbidity than excess fat in the lower
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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body [1]. Central obesity is associated with insulin resistance (IR) and this condition predis-
poses to cardiovascular disease (CVD) [2]. Adipose tissue (AT) is not only an energy storage
organ but also produces adipokines, which contribute to the development of subclinical
inflammation [3]. The compounds released from AT are capable of affecting endothelial cell
(EC) functions [4]. The mechanism of obesity-induced endothelial dysfunction is multifactorial
mainly due to the omnidirectional impact of various adipokines, leading to the following
abnormalities such as elevated blood pressure, formation of atherosclerotic plaques, oxidative
stress, prothrombotic state and alterations in glucose and lipid metabolism [5]. AT remodeling
is pathologically accelerated in an obese state due to local hypoxia. Reduced angiogenesis is a
severe immune cell infiltration with subsequent pro-inflammatory responses which addition-
ally deteriorates EC functions [6]. Therefore, one of the main goals of therapeutic interventions
in obesity is to correct abnormalities in EC function and to protect endothelial integrity.
It is believed that EC dysfunction in obesity can be reduced by caloric restriction (CR), but it is
unclear whether this benefit requires significant or moderate weight loss. In recent studies
conducted on overweight humans, short- and long-lasting CR (6–52 weeks) have shown to
improve a number of health outcomes [7–9]. The important issue is that most individuals have
difficulty sustaining prolonged CR and the improvement of EC function may be problematic
to achieve. Our cooperation with physicians, dieticians and psychologists allows us to claim
that it is usually optimal for obese patients if CR is not so burdensome and yet, at the same
time, effective. Therefore, we propose a mild CR as a way to lose body weight in obese
individuals. Such a type of CR reflects a real-life situation and seems to be optimal to achieve
an improvement of EC.
2. Adipose tissue
AT was earlier characterized as a connective tissue which stores triglycerides. An increase in
global obesity and diabetes has attracted great interest to the function of this tissue. Nowa-
days, AT is considered an important regulator of energy balance, which plays a major role in
nutrient homeostasis after feeding and releases free fatty acids (FFAs) during fasting. As such,
it is regarded as an endocrine organ producing adipokines, which affect many organs and thus
the homeostasis in the body (Figure 1).
AT is mainly found in subcutaneous and visceral depots. In obesity, AT is accumulated in
different organs, including heart, liver, kidneys, bone marrow, lungs and the adventitia of
major blood vessels, where secreted adipokines affect their function. Excess visceral adiposity
is strongly correlated with IR, hypertension and dyslipidemia, which contribute to high rates
of mortality and morbidity [3, 10]. Most adipokines, which stimulate inflammatory responses,
are dysregulated in obesity and promote obesity-induced metabolic dysfunction, leading to
CVD. The production of pro-inflammatory cytokines by AT is upregulated in an obese state
(Table 1) while the secretion of anti-inflammatory factors is reduced (Table 2).
Adipocytes are divided into two types: white adipocytes and brown adipocytes. Brown adi-
pocyte tissue (BAT) converts nutrients into chemical energy in the form of heat. Brown fat cells
Endothelial Dysfunction - Old Concepts and New Challenges252
express a unique thermogenic and mitochondrial genetic program that promotes mitochon-
drial biogenesis, energy uncoupling and energy dissipation, in turn providing essential heat to
the organism. Energy dissipation is possible in the presence of large amounts of mitochondria
Figure 1. The impact of adipose tissue on multiple organs mediated by various factors released from adipocytes [3].
Pro-inflammatory adipokines
Adipokine Function
Leptin Appetite control though the central nervous system
Resistin Induces insulin resistance by stimulating the Il-6 and TNF-α production
in macrophages
Retinol-binding protein 4 (RBP4) Induces insulin resistance by influencing glucose homeostasis
Lipocalin 2 (neutrophil gelatinase-associated
lipocalin)
Promotes insulin resistance through TNF-α secretion from adipocytes
Angiopoietin-like protein 2 (ANGPTL-2) Activates inflammatory response in endothelium and promotes insulin
resistance
Tumor necrosis factor-α (TNF-α) Attenuates insulin signaling in muscles and adipose tissue (IR)
Interleukin 6 (Il-6) Involved in insulin resistance. It has various function in different organs
Interleukin 18 (IL-18) Inflammation, involved in plaque instability and endothelial activation
Monocyte chemoattractant protein 1
(MCP-1/CCL-2)
Inflammation, involved in monocyte chemotaxis
CXC-chemokine ligand 5 (CXCL5) Secreted from macrophages in AT. Responsible for IR
Chemerin Inflammation, involved in monocyte chemotaxis and stimulates lipolysis
Nicotinamide phosphor ribosyltransferase
(NAmPT, Visfatin)
Modulator of B cell differentiation, correlates with visceral adiposity,
monocyte chemoattractant
Table 1. Pro-inflammatory adipokines and their functions [11, 12].
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with the uncoupling protein-1 (UCP-1). This provides heat rather than adenosine triphosphate
(ATP) production [13].
White adipose tissue (WAT) stores triglycerides during energy consumption and releases fatty
acids during starvation. WAT is also an active endocrine organ that secretes a large number of
adipokines. Adipokines act centrally to regulate appetite and energy expenditure. They
peripherally affect insulin sensitivity, promote subclinical inflammation and lipid uptake and
accommodate the conversion of steroid hormones. Fats can be classified as subcutaneous or
visceral. WAT has a specific morphology. Histologically, subcutaneous fat contains mature
large adipocytes, whereas visceral fat consists of small adipocytes. Subcutaneous and visceral
depots contribute to metabolism in different ways. An increased subcutaneous fat deposition
in the form of “pear-shaped” or female pattern of distribution might protect against certain
aspects of metabolic dysfunction, especially against IR [14, 15]. However, visceral depots, in an
“apple” or male pattern of distribution, are thought to be associated with metabolic complica-
tions and appear to increase the risk of diabetes, hyperlipidemia and CVD [16]. It has become
popular to term subcutaneous adipose as ‘good fat’ and visceral as ‘bad fat’.
3. AT remodeling in obesity
3.1. Infiltration of immune cells into AT
AT is mainly comprised of adipocytes, although other cell types contribute to its growth and
function. These include pre-adipocytes, lymphocytes, macrophages, fibroblasts and vascular
cells (Figure 2). AT can respond rapidly and dynamically to nutrient deprivation and also to its
excess. One of the unique attributes of AT is its incredible capacity to change its dimensions.
This effect can be accomplished by increasing the size of adipose cells (hypertrophy) or by
recruiting new adipocytes from the resident pool of progenitors (hyperplasia).
AT expands first by hypertrophy until a critical threshold is reached, upon which signals are
released for the induction of preadipocyte proliferation and differentiation (hyperplasia) [17].
Anti-inflammatory adipokines
Adipokine Main function
Adiponectin Negatively correlates with inflammation and visceral fat accumulation,
protects against metabolic dysfunction and IR
Secreted frizzled-related protein 5 (SFRP 5) Anti-inflammatory, important for insulin sensitivity
Visceral adipose tissue-derived serine
protease inhibitor (Vaspin)
Positively correlates with BMI and insulin sensitivity, increases glucose
tolerance
Omentin-1 Expressed in visceral fat, protects against IR. Its level is reduced in obesity
Apelin It plays different functions in various organs. Its production is enhanced by
insulin. Has angiogenic and hypotensive properties
Table 2. Anti-inflammatory adipokines and their functions [11, 12].
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AT remodeling is pathologically accelerated in an obese state with reduced angiogenesis,
extracellular matrix (ECM) overproduction and severe immune cell infiltration with subse-
quent pro-inflammatory responses. The large infiltration of macrophages in AT is linked to a
systemic inflammation and IR. Moreover, the accumulation of macrophages is proportional to
adiposity, and a sustained weight loss results in the lowering of inflammation, which suggests
that this infiltration is reversible. Macrophages are also more abundant in the visceral than
subcutaneous AT [6, 12]. Resident adipose macrophages display remarkable heterogeneity in
their activities and functions. Hypertrophic adipocytes produce chemotactic factors, which
promote monocyte accumulation in AT.
Macrophages can be classified into two broad groups: M1 and M2, based on the expression of
particular antigens. Lumeng et al. proposed a model which emphasized that obesity is accom-
panied by a transformation of M2 anti-inflammatory macrophages (that are primarily accu-
mulated during a negative energy balance) to more pro-inflammatory M1 macrophages [18].
The subsets of T cells presented in AT have been seen to be implicated in the macrophage
activation. T helper cells (CD4+) are present in a large numbers in the AT of lean persons and
have a protective effect by impeding M1 macrophages, resulting in increased insulin sensitiv-
ity. T cytotoxic cell (CD8+) can start the mobilization and activation of M1 macrophages and in
this way it promotes an inflammation associated with IR. The M1 population positively
correlates with IR and is characterized by overnutrition, where FFAs stimulate its pro-
inflammatory responses [18]. In a lean state, resident macrophages are polarized toward the
M2 state, which expresses a combination of anti-inflammatory factors that may help to pre-
serve the normal adipocyte function by promoting AT repair and angiogenesis. Conversely,
M1 macrophages induced by pro-inflammatory mediators express a repertoire of pro-
inflammatory factors, which include tumor necrosis factor alpha (TNF-α), interleukin 6 (Il-6),
inducible nitric oxidase synthase (iNOS) and produce reactive oxygen species (ROS) [3, 6]. The
Figure 2. Components of adipose tissue [3, 12]. Abbreviations: AT, adipose tissue; ECM, extracellular matrix.
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key function of macrophages is to remove apoptotic cells in an immunologically silent manner to
prevent the release of harmful substances. The presence of apoptotic adipocytes surrounded by
M1 macrophages (forming the so-called crown-like structures) is a characteristic feature in the
obese with a full metabolic dysfunction. This pro-inflammatory state in AT is due to an impair-
ment of the macrophage-mediated phagocytic process. The fibroblasts from metabolically dys-
functional AT produce excess ECM components that may contribute to metabolic dysregulation.
The intercellular communication within AT is required for normal metabolic function. The
obesity-associated changes in the cellular composition of AT lead to a modification of adipokine
secretion [18, 19]. Consequently, obese patients can be categorized into those that have a fully
dysfunctional metabolic phenotype and those that have a mildly dysfunctional metabolic phe-
notype (Figure 3) [19].
3.2. Angiogenesis in AT
Angiogenesis plays a central role in various physiological processes in a human body, not only
during fetal development. Angiogenesis can be a hallmark of wound healing, menstrual cycle,
cancer and various ischemic and inflammatory diseases. The pivotal process of angiogenesis
can be simply described in multiple steps. First, angiogenic stimuli cause an increase in EC
permeability and proliferation. Second, the proteolysis of the basement membrane compo-
nents is a necessary process to promote the invasion of EC into the stroma of the neighboring
Figure 3. Adiposity-related metabolic dysfunction [3, 12]. Abbreviations: AT, adipose tissue; CD4+, T helper cell; CD8+, T
cytotoxic cell;$, without changes.
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tissue, in which the supportive activity of the tissue plasminogen activator system (t-PA and
uPA—urokinase-type plasminogen activator) and matrix metalloproteinases (MMPs) are
required. Third, the migrated ECs trigger lumen formation as the sprout forms a multicellular
structure. Finally, the capillary is stabilized through the construction of a basement membrane,
an adherent junction and ECs [20, 21].
AT possesses a relatively dense network of blood capillaries, ensuring an adequate exposure to
nutrients and oxygen. The AT vasculature serves to transport systemic lipids to their storage
depot in adipocytes, and transfers factors (e.g. adipokines) and nutrients (e.g. FFAs) from these
cells in times of metabolic need. The microvasculature of AT is necessary for the expansion of
adipose mass not only to prevent hypoxia, but also as a potential source of adipocyte pro-
genitors in WAT. The blood capillary network also contributes to immunity and inflammation.
AT macrophages serve multiple functions: (i) removal of necrotic adipocytes, (ii) production of
pro-inflammatory and (iii) pro-angiogenic mediators [3, 22]. Obesity reduces the density of
capillaries in AT, leading to localized hypoxia. The effect of hypoxia in obesity is complex and
could be explained by: (i) the proportion of the cardiac output and blood flow that goes to WAT
is not increased in the obese despite the expansion of the tissue mass, (ii) obese subjects do not
exhibit the postprandial increase in the blood flow to AT that occurs in lean subjects and (iii)
hypertrophied adipocytes are larger than normal, which impedes oxygen delivery to fat cells.
Tissue hypoxia drives many cellular and molecular mechanisms. The first cellular mechanism
responsible for local inflammation is macrophages recruitment. The necrosis of adipocytes,
driven by hypoxia, is a prominent phagocytic stimulus that regulates macrophages infiltration.
The second mechanism responsible for adipose inflammation is lipotoxicity. FFAs released from
hypertrophic adipocytes could be transported to the liver and stored in lipid droplets. They
could also be re-esterified to triglycerides in adipocytes. Those which escape re-esterification
play a critical role as a primary energy source in several organs during prolonged fasting. FFAs
are also ligands for TLR 4 (Toll-like receptor) presented in macrophages. FFAs binding with TLR
4 activate the inflammatory signaling cascade (NF-κB—nuclear factor kappa-B). The third
mechanism is directly associated with oxygen deprivation (Figure 4) [22–24].
Hypoxia in AT has been investigated in human and animal models. Many adipokines related
to inflammation (leptin, TNF-α and Il-6), MMPs, growth factors (VEGF—vascular growth
factor and bFGF—basic fibroblast growth factor) are elevated in hypoxia [26]. The master
regulator of hypoxia is hypoxia-inducible factor (HIF-1). It is a heterodimer composed of an
oxygen-sensitive HIF-1α subunit and a constitutively expressed HIF-1β, which is not directly
regulated by oxygen. A substantial number of genes are recognized to be hypoxia sensitive.
The target genes include those involved in angiogenesis, cell proliferation, survival, apoptosis,
vascular tone, glucose and energy metabolism. The genes, which regulate leptin, VEGF and
MMPs expression, are controlled by HIF-1 and become elevated in response to low oxygen
partial pressure (pO2) in adipocytes. At the same time, the adiponectin gene is downregulated
[27]. Glucose uptake by human adipocytes is strongly stimulated by hypoxia, presumably as a
consequence of an increased amount of glucose transporters (GLUT). This may results in
changes in insulin sensitivity. An experimental model of intermittent hypoxia has been shown
to induce IR [28]. The effect of hypoxia on the WAT function has been discussed in terms of
adipocytes, reflecting the fact that these are the cells that are characteristic of AT. Adipocytes
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generally account for no more than 50% of the total cell content of WAT (Figure 2). The other
non-adipocyte cells such as immune cells, vascular cells and pre-adipocytes are also affected by
hypoxia, producing inflammatory mediators. There are several transcription factors which are
implicated in molecular response to hypoxia, including NF-κB, which modulates the transcrip-
tion of target pro-inflammatory genes. However, the pivotal role in response to hypoxia is
played by HIF-1, which leads to proper angiogenesis. Hypoxia promotes angiogenesis by
stimulating VEGF production in ECs, which plays a central role in angiogenesis and neovascu-
larization. It is a potent mitogen for vascular ECs. It also releases other mitogenic molecules
(PDGF—platelet-derived growth factor, bFGF, ET-1—endothelin-1) for smooth muscle cells
and many pro-inflammatory mediators (Il-6, Il-1α—interleukin 1α, Il-8—interleukin 8, MCP-1
—monocyte chemoattractant protein, iNOS) modulating the angiogenesis process [29].
Hypoxia can also act adversely by inhibiting the angiogenic response and by promoting EC
death and apoptosis [30, 31]. The two major responses of ECs have been observed depending
on the degree and duration of oxygen deficiency. Firstly, acute hypoxia rapidly activates the
ECs to release chemoattractants (Il-8, PAF—platelet activating factor and MCP-1). This is a
direct process which does not need gene induction. These inflammatory mediators are able to
recruit and promote the adherence of leukocyte and platelets to endothelium, leading to a local
Figure 4. The response of adipocytes and endothelium to hypoxia [25, 26]. Abbreviations: HIF, hypoxia-inducible factor; Il-
6, interleukin 6; MMP, matrix metalloproteinase; VEGF, vascular endothelial growth factor; GLUT, glucose transporter;
HO, heme oxygenase; NO, nitric oxide; iNOS, inducible nitric oxide synthase; ET-1, endothelin 1; ICAM-1, intercellular
cell adhesion molecule-1, PAF, platelet-activating factor; vWF, von Wilebrand factor; Il-8, interleukin 8; COX-2, cycloox-
ygenase 2; PDGF, platelet-derived growth factor; TF, tissue factor; TM, thrombomodulin.
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inflammatory reaction in ischemic tissue. Secondly, longer periods of hypoxia increase the
expression of specific genes encoding cytokines, growth factors and pro-coagulation molecules
by HIF-1 activation [25]. Hypoxia in EC also induces NF-κB activation. This promotes the
synthesis of pro-inflammatory cytokines, prostaglandins and adhesion molecules, which sup-
ports the further transmigration of leucocytes to AT. The adverse effect of NF-κB expression in
hypoxia is EC death and apoptosis (Figure 4) [31].
EC proliferation and migration, crucial for angiogenesis, could also be affected by hypoxia.
The expression of VEGF and its receptor Flt-1 are upregulated by hypoxic endothelium. Both
VEGF and its receptor Flt-1 are responsible for the strong mitogenic response in a hypoxic
condition. In spite of VEGF overexpression, hypoxia can also paradoxically inhibit the angio-
genic response, which could be blocked by a soluble form of VEGFR1 (Flt-1) [29, 30].
Hypoxia can also affect vascular tone, favorable for vasoconstriction. The basal and stimulated
nitric oxide (NO) release by endothelium is quickly inhibited by hypoxia. This seems to be due
to a decrease in the constitutive endothelial NO synthase (eNOS) expression and the concom-
itant increase in ET-1 release. In conclusion, the increased production of different mitogens
combined with the suppression of endothelial NO would be expected during vascular
remodeling [32]. Additionally, hypoxia increases the procoagulant activity, which correlates
with a marked decrease of thrombomodulin (TM) and an increase in the tissue factor (TF)
expression (Figure 4) [25].
Angiogenesis plays a critical role in healthy AT expansion. To better understand this issue, the
overexpressed HIF-1α in adipocytes in a transgenic mouse model was analyzed during hyp-
oxia [33]. It was observed that there was no expression of the classical HIF-1α target genes such
as VEGF, or any components of angiogenic or anaerobic glucose pathway was registered.
Surprisingly, scientists observed fibrosis, which was induced by the upregulation of lysyl
oxidase (LOX), elastin, collagens (I, III) and the tissue inhibitor of MMP-1 (TIMP-1). They
proposed a hypothesis that the accumulation of ECM in WAT during hypoxia causes local
fibrosis with a subsequent inflammatory response and IR [33]. Briefly, a healthy AT expansion
consists of adequate angiogenic response and appropriate remodeling of the ECM. In contrast,
a pathological AT expansion consists of a massive enlargement of existing adipocytes, reduced
angiogenesis and consequent hypoxia [33, 34] (Figure 5). It has been reported that obese mice
receiving anti-angiogenic reagents have a reduced body weight while their adipose mass
shows increased metabolic rates [35]. This is due to the fact that there is a close interplay
between adipogenesis and angiogenesis in obesity [36].
In the end of this section, it is worth to mention about some important angiogenic and
angiostatic factors crucial for appropriate angiogenesis. Obesity is known to modify these
mediators [37]. Below it is shortly discussed the essence of action of pro-angiogenic factors
such as bFGF, IGF-1 (insulin growth factor-1) and Ang-1 (angiopoetin-1) and angiostatic
factors such as TSP-1 (thrombospondin), endostatin, Ang-2 (angiopoetin-2), IP-10 (interferon-
induced protein) and IFN-γ (interferon-γ).
bFGF is another essential pro-angiogenic factor besides VEGF. It changes ECs morphology,
increases proliferation, migration and production of metalloproteinases which facilitates the
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degradation of ECM. The autocrine secretion of bFGF by ECs is crucial for their migration and
invasiveness [38]. Tsuboi et al. found correlations between bFGF and metalloproteinases in
endothelial culture medium and suggested that expression of metalloproteinases is critical for
migration and invasiveness of ECs and finally in the tube formations [39]. The clinical data
analyzing the correlation between bFGF and abdominal obesity are still inconclusive [40, 41].
IGF-1 also called somatomedin C, has similar structure to insulin and possesses the affinity to
insulin receptor. It is produced in the liver in response to growth hormone stimulation. As a
mitogenic and anabolic factor, its effect is particularly important for the muscle, neural,
hepatic, renal, lung and hematopoietic cells [42]. Additionally, the reduction of IGF-1 in
rodents but not in humans is one of the most important effects of CR, which explains the
maintenance of animal lifespan [43].
The key angiogenesis processes such as proliferation and migration are regulated by anti-
angiogenic TSP-1. Bagavandoss and Wilks documented the anti-angiogenic effects of TSP-1 in
various types of ECs, emphasize that its anti-angiogenic effect is mainly due to the inhibitory
effect of endothelial proliferation [44]. Nowadays, TSP-1 is also classified as adipokine secreted
by visceral fat, predisposing to IR and subclinical inflammation [45].
Endostatin is an endogenous inhibitor of angiogenesis, altering the action of VEGF and bFGF.
The N-terminal sequence of this inhibitor is identical with a C-terminal fragment of XVIII
collagen, presented in the basal membrane and extracellular matrix. Endostatin inhibits the
proliferation, migration, adhesion and ability to tube formation. It blocks multiple signaling
pathways, such TNF-α and NF-κB pathways, adhesion and also clotting process [46, 47].
Endostatin administration may reduce adipose tissue growth in animal model [35].
Figure 5. Healthy and unhealthy adipose tissue expansion [6, 26].
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Maturation and stabilization of the blood vessels in the final stages of angiogenesis are con-
trolled by a pair of opposing proteins—Ang-1 and Ang-2 [42]. Both proteins bind to the same
Tie-2 (angiopoetin tyrosin kinase receptor) receptor on the surface of ECs resulting in opposite
effects: Ang-1 acts as agonist and Ang-2 acts as antagonist. Ang-1 is secreted by adipocytes
and Ang-2 by ECs [48]. Ang-1 concentration correlates with the percentage of adipose tissue in
the body [49].
IP-10 is a chemotactic factor for T lymphocytes, produced by various cells such as monocytes,
endothelium and fibroblasts in response to IFN-γ stimulation [50]. IP-10 overexpression occurs
in subcutaneous fat tissue in obese patients [51], but no differences between obese patients
with or without diabetes were reported [52].
Infiltrating macrophages and lymphocytes are an important cause of inflammation and IR in
AT [3, 18, 19]. IFN-γ produced by lymphocytes changes the phenotype of macrophages to
more pro-inflammatory—M1 [53]. Central obesity especially predisposes to high IFN-γ level
[54] which is not modified by hypoglycemic treatment [55].
3.3. Crosstalk between adipocytes and endothelial cells
Vascular ECs play a major role in maintaining cardiovascular homeostasis. In addition to
providing a physical barrier between the vessel wall and blood lumen, endothelium secretes a
number of mediators that regulate vascular tone, coagulation, fibrinolysis and blood cells
trafficking. Endothelium can extend its repertoire of functions by adaptation to various stim-
uli, including mechanical stress, oxidative and metabolic stress, inflammation, hypoxia and
many others [32].
Obesity is a component of a metabolic syndrome, a constellation of metabolic risk factors that
consist of (i) dyslipidemia, (ii) hypertension, (iii) glucose intolerance, (iv) IR, (v) prothrombotic
and (vi) a pro-inflammatory state. Hyperglycemia, dyslipidemia, hyperinsulinemia and
adipokines derived from AT play a more dominant role in microvascular complications. In
addition to the endothelial pro-inflammatory activation and the decrease in NO production,
endothelial barrier increases its permeability due to increased VEGF synthesis in response to
hypoxia (HIF-1 activation) and the presence of FFAs released from adipose tissue as an effect
of insulin resistance (Figure 6) [56]. The strong interaction between AT pro-inflammatory
adipokines and endothelium makes obese patients much more prone to CVD [2]. Hanzu et al.
exposed endothelium on the medium supplemented with extracts obtained from the visceral
fat taken from obese and lean subjects. The adipokines secreted from the visceral fat taken
from the obese adversely affected endothelium by increasing the expression of adhesion
molecules and von Willebrand factor (vWF). That, in turn, intensified the endothelial cell
proliferation and changed EC morphology. Researchers concluded that the observed effects
are a result of the activation of NF-κB transcription factor signaling pathways [57].
Endothelial dysfunction in obesity is a multifactorial process and has different molecular
aspects. Obesity is characterized by an increased generation of ROS. Because of endoplasmic
reticulum stress and mitochondrial dysfunction, ROS are generated in the vascular wall and
hypertrophied adipocytes. The effect of ROS on vascular function critically depends on their
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quantity. When formed in low amounts, they can act as intracellular secondary messengers,
modulating the growth response of vascular smooth muscle cells and fibroblasts. A higher
amount of ROS can cause widespread cellular toxicity. Many enzymes of the mitochondrial
electron transport chain, such as COX (cyclooxygenase), LOX (lipooxygenase), xantin oxidase,
myeloperoxidase, NADPH oxidase, uncoupling eNOS and leptin are the major contributors of
ROS production in obesity, leading to a decrease in NO production and an increased produc-
tion of vasoconstrictor ET-1. NO bioavailability is lowered as a result of peroxynitrite forma-
tion (ONOO). Peroxinitrite is also created as a result of the iNOS activity which is stimulated
by an exaggerated production of TNF-α. The enzyme produces NO in a large amount and
when combined with the superoxide (O2
), anion creates cytotoxic peroxinitrite. Finally, NO
production can also be inhibited by an endogenous inhibitor—asymmetric dimethylarginine
(ADMA), which competitively inhibits eNOS. The ADMA level is elevated in obese patients
and could serve as another mechanism which alters the NO level [4, 32].
ROS accumulation and pro-inflammatory adipokines are implicated in the activation of NF-
κB, which is involved in the immune response, apoptosis and inflammation regulating the
expression of growth factors, pro-inflammatory cytokines and adhesion molecules [31]. Many
products of the genes regulated by NF-κB also, in turn, activate NF-κB (e.g. TNF-α). Pro-
inflammatory mediators created by NF-κB signaling, and derived from AT are implicated in
EC activation with an increased expression of adhesion molecules (ICAM-1—intercellular cell
adhesion molecule-1, VCAM-1—vascular cell adhesion molecule and selectins), and an
increased production of chemotactic factors (MCP-1 and Il-8). This promotes the adhesion
and migration of circulating leukocytes, initiating atherosclerotic lesion [32, 56].
ECs use glucose and FFAs as nutrients. Non-esterified FFAs are liberated from triglyceride-rich
lipoproteins by the endothelial lipoprotein lipase. The endothelial glucose uptake is insulin
Figure 6. Crosstalk between adipocytes and endothelial cells [3, 4, 58]. Abbreviations: Il-6, interleukin 6; TNF-alpha, tumor
necrosis factor-alpha; NF-κB, transcriptional factor; HIF-1α, transcriptional factor; FFA, free fatty acid; NO, nitric oxide;
VEGF, vascular endothelial growth factor.
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independent. Physiologically, glucose uptake in endothelium occurs via the glucose trans-
porter GLUT-1. The insulin receptor is presented on the EC surface. Insulin can dilate arteries
by the PI3K-Akt-eNOS signaling pathway that stimulates NO release and is also able to
rapidly release ET-1 (via MEK-ERK1/2-ET-1 pathway). Both effects occur via the insulin recep-
tor [56]. Central obesity is associated with an increased FFAs level. Elevated FFAs may impair
endothelial function as measured by flow-mediated dilatation (FMD) and might affect insulin-
mediated vasodilatation [56]. FFAs alter some important intracellular pathways: they could
affect ion transport (Na+, K+ and Ca2+), vascular reactivity (PKC—protein kinase C) cell growth
and ROS generation (NADPH oxidase). This action may have potentially relevant implications
for obese patients, leading to a decrease in NO bioavailability. Another possible mechanism,
induced by elevated FFAs, that could impair vasodilatation in obese patients, is the reduction
of prostacyclin (PGI2) production [32, 56].
The most essential adipokines implicated in EC dysfunction are leptin and adiponectin
(Tables 1 and 2). Their specific properties affecting endothelium and angiogenesis processes
are described below.
Leptin is secreted from WAT in proportion to the size of AT. It exerts a pressor effect by
activating the central nervous system, which inhibits appetite. Its adverse multidirectional
effects exerted on ECs include: (i) promoting oxidative stress, (ii) promoting thrombosis by
inhibiting thrombomodulin level and increasing tissue factor, (iii) stimulating angiogenesis by
promoting ECs proliferation and expression of adhesion molecules, MMPs and VEGF and (iv)
stimulating pro-inflammatory cytokines such as TNF-α, Il-6 and MCP-1 [4, 59]. This stimulat-
ing effect of pro-inflammatory cytokines is responsible for ECs activation, and may cause
hypertension. However, it has been recently shown that leptin may also have a vasodilatory
effect. This heterogeneous effect relates to the predominant role of the endothelium-derived
hyperpolarizing factor (EDHF) mechanism and is induced by a direct effect of NO release from
ECs and an indirect effect of NO release from adipocytes, which triggered leptin, activates
eNOS [60].
Adiponectin is the most abundantly secreted adipokine (plasma concentration: 2–20 μg/ml).
Globular adiponectin (gAD) and full-length adiponectin (fAD) exert their effect by two recep-
tors (Adipo R1 and Adipo R2). Both receptors are presented on ECs. Generally, adiponectin is
responsible for insulin sensitivity by improving carbohydrate and lipid metabolism.
Adiponectin exerts its insulin-sensitizing effect by increasing β-oxidation of FFAs, reducing
serum triglyceride and FFAs. It also has antiatherogenic and anti-inflammatory properties. The
production of adiponectin by adipocytes is inhibited by pro-inflammatory factors such as
TNF-α and Il-6 as well as hypoxia and oxidative stress. Its antiatherogenic and anti-
inflammatory properties within the vascular wall are mediated via: (i) increased phosphoryla-
tion of insulin receptor, (ii) modulation of NF-κB pathway (inhibiting adhesion molecules), (iii)
inhibition of foam cell formation, (iv) decreased proliferation and migration of smooth muscle
cells and (v) stimulation of NO production in ECs. The plasma adiponectin level highly
correlates with the vasodilatory response. Conversely, hypoadiponectinemia is associated with
a blunted endothelial function and coronary artery disease [3, 12]. Adiponectin can also induce
angiogenesis by promoting signaling cross talk (AMPK-Akt-eNOS) in endothelium. Interestingly, a
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potent inhibition of endothelial angiogenic properties like proliferation and migration was also
observed [61, 62].
The major risk factors for coronary artery disease, present in obese patients, impair the endo-
thelium response to acetylcholine (ACh), which induces a paradoxical vasoconstriction rather
than vasodilatation [32]. The endothelial damage can also be assessed by measuring some
endothelial-derived markers. Hemostatic factors such as procoagulant von Wilebrant factor
and anticoagulant TM are elevated in obesity. They are not only the markers of EC activation
but also the markers of EC membrane injury. The factors responsible for EC activation, which
mediate the interaction between leukocytes, platelets and the endothelium, are also elevated in
obese patients (E-selectin, VCAM-1 and ICAM-1). These factors provide potentially relevant
information about the EC condition and the tendency to vasoconstriction, coagulation, platelet
aggregation and future cardiovascular morbidity and mortality [4, 32].
4. Caloric restriction
Caloric restriction (CR) is the most effective and reproducible dietary intervention known to
affect aging process and increase the healthy lifespan in various model organisms from unicel-
lular yeast to rodents and primates. There is no agreement on how severe a CR must be in
order to confer benefits in different organs and systems. However, CR which in most cases
involves a 20–40% reduction of dietary requirement relative to normal intake is a severe
intervention that results in both beneficial and detrimental effects [63, 64]. Studies show that
CR does not need to be prolonged for a long time to be effective, with the advantage that short-
term CR is easier to include in clinical practice. In this context, a genomic analysis revealed that
the results obtained from short- and long-term CR were similar [65]. It is one of the most
common and cost-effective interventions used to induce body weight reduction and control
CVD risk factors. It is important to note that the induction of negative energy balance is
mandatory for achieving the metabolic benefits of weight loss. Benefits on CV risk factors by
reducing the daily caloric intake have been widely described in obese subjects [7, 65–67]. CR
reduces body weight, waist circumferences (visceral fat), serum lipids, insulin level and
improves insulin sensitivity. The decrease in adiposity leads to a reduction of pro-
inflammatory adipokines (e.g. leptin, Il-6, TNF-α, etc.), oxidative stress as well as to an increase
in the anti-inflammatory adipokines (e.g. adiponectin, omentin, etc.) [7, 66–68]. Weight loss
enhances FMD, which significantly improves endothelial function in vitro [8].
The molecular mechanism of CR is complex. It involves downregulation of insulin (also IGF-1
pathway) and insulin-like signaling, the signaling of mTOR (mammalian target of rapamycin)
kinase pathway, a rise in the energy balance modulator sirtuins (particularly sirtuin 1) as well as a
decrease in pro-inflammatory mediators, growth factors and ROS production [63]. Especially
sirtuins are responsible for some beneficial and longevity-promoting effects of CR inmany species
of animals—from fruit flies to mammals. They are implicated in many physiological effects as
control of circadian clock, mitochondrial biogenesis, aging, apoptosis and inflammation [69].
Large observational data support a detrimental effect of obesity on the risk of several cancers,
including breast and colon cancer, two of themost common cancers inNorthAmerica and Europe
[63]. The most important causes predisposing to cancer development in obese people are elevated
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female sex hormones, hyperinsulinemia and a high level of pro-angiogenic and pro-inflammatory
factors. Relatively little data exist on the effects of weight gain or weight loss on the risk of cancers
[63]. The lack of data on weight loss is likely a function of the small number of individuals able to
achieve a sustainedweight loss. It is relatively often emphasized that the risk of colorectal cancer is
reduced due to weight loss [70]. The best evidence that weight loss can reduce the risk of cancer
comes from recent studies in bariatric surgery patients [71]. Tumors becomemalignantwhen they
attract new blood vessels. Angiogenic switch could be slowed down when special drugs which
can stop a key angiogenic mediator—VEGF are used. This concept of angiogenesis was first
described by the pediatric surgeon Folkma [72]. The balance between pro- and anti-angiogenic
factors allows neoangiogenesis to occur. Angiogenesis could be inhibited through an action on
VEGF, bFGF and MMPs. Additionally, high level of mitogenic insulin resistance (IR) correlates
with some angiogenic factors [73]. It is well documented that pro-inflammatory cytokines in
obesity are mitogenic and pro-angiogenic. CR can decrease (i) insulin signaling, (ii) angiogenic
mediators, (iii) inflammation lowering pro-inflammatory adipokines,NF-κB signaling andCOX-2
expression, (iv) pro-angiogenic leptin and (v) increase anti-angiogenic adiponectin [74–76]. This
anti-inflammatory effect of CR contributes significantly to crucial endothelial function in regulat-
ing angiogenesis, hemostasis, vascular tone and vascular wall integrity. This modified effect of CR
exerted on endothelium is not only caused by decreased inflammation and angiogenic factors, but
also by regulating fibrinolysis, the integrity of the basement membrane and extracellular matrix
proteins [20]. Plasminogen activator inhibitor-1 (PAI-1), t-PA, u-PA and also MMPs are involved
in angiogenesis. The circulating levels of PAI-1 and MMPs are consistently decreased in response
to CR [4]. Rats fed a diet reduced by 40% showed improved vascular EC function, reduced free
radical production, expression of NF-κB and a decreased expression of pro-inflammatory genes
such as IL-6, TNF-α, sICAM-1 or iNOS [77]. Furthermore, the positive effect of a reduced caloric
intake leads to an increased expression of eNOS and transcriptional factor Nrf2 (nuclear factor
erythroid 2-related factor), which produces anti-oxidative stress proteins, and activates the VEGF-
dependent metabolic pathways [64, 74, 77].
5. Effects of moderate caloric restriction on obese patients—personal
observations
In the next section, we would like to present the data of our studies where we investigated the
effect of moderate CR on: (i) endothelial cell function especially involved in angiogenesis, (ii)
production of adipokines, angiogenic and angiostatic factor and (iii) oxidative stress. Based on
our previous studies that have already been published [78] and the data from the literature, we
hypothesized that moderate CR, because it is not so burdensome and reflect a real-life situa-
tion, seems to be optimal to achieve an improvement of EC.
5.1. Patients and experimental design
To assess the impact of moderate CR, we recruited 50 obese patients (age 37  11 years, BMI:
37.7  6.1 kg/m2, 72% women). The study was approved by the institutional Ethics Committee
(decision number: 217/11) and all patients submitted their informed consent. The exclusion
criteria involved overt diabetes, congestive heart failure, an acute coronary syndrome over the
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past 6 months, malignant or systemic illness, pregnancy, bariatric surgery, a known eating
disorder and a change in body weight greater than 2 kg over the past 3 months. Glucose
intolerance and hypertension are very common abnormalities seen in obese patients; therefore
we decided to include them in our study. Glucose intolerance was the most common disorder
(46%). Therefore, the obese patients were divided into the normoglycemic (N) obese (age
37  12 years, BMI: 36.2  6.1 kg/m2, 78% women); treated only with a diet (n = 27) and the
obese with glucose intolerance (GI) (age 38  10 years, BMI: 38.8  7.6 kg/m2, 70% women)
and treated with a diet and a hypoglycemic drug metformin (n = 23). The results were derived
from all 50 obese patients who completed the 8-week mild CR program and as a result of this
intervention they reduced their body weight.
The dietary intervention lasted 8 weeks and aimed to produce a 15–30% energy deficit (a
reduction by 300–500 kcal/day). The patients’ basal metabolic rate (BMR) was calculated
according to the Harris-Benedict equation and corrected for physical activity according to
WHO criteria [79]. The estimated BMR ranged between 1454 and 2045 kcal/d [79] and all
patients displayed low physical activity (physical activity factor: 1.4) [80]. The participants
were supervised twice a week by a dietician, who designed individualized dietary plans that
supplied energy from similar sources but took into account patients’ food preferences. The diet
was composed of: 25% fat: saturated 7%; 20–25% protein; 50–55% carbohydrates: complex 45–
50%, saccharose <10% (exemplary diet is presented in appendix). To assess only the effect of
mild CR, physical activity was not recommended.
5.2. Detected parameters
To minimize diurnal variations, fasting blood samples were always collected between 7.30 and
9.00 am. Samples of serum were aliquoted and stored at 80C until assayed. Before and after
CR we measured the following parameters:
• mediators of ECs function (sICAM-1, sVCAM-1, sE-selectin, TM, vWF, PAI-1, ADMA, NO);
• proliferation, migration and invasion using endothelial cell culture in vitro after exposition
to medium supplemented with 20% serum taken before and after CR;
• adipokines (leptin, adiponectin, vaspin, rezistin, TNF-α, Il-6);
• angiogenic factors (VEGF, bFGF, Ang-1, IGF-1, Il-8, MMP-2, MMP-9);
• angiostatic factors (Ang-2, endostatin, TSB-1, TIMP-1, INF-γ, IP-10);
• oxidative stress (TAS—total antioxidant status, SOD—superoxide dismutase, catalase,
ROS production by ECs in vitro);
• fat content;
• homeostatic model of assessment of insulin resistance (HOMA-IR).
5.3. Methods
Using the in vitro culture (HUVEC lineEA.hy926), we evaluated endothelial pro-angiogenic
processes, such as proliferation, migration and invasion.
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• Cell proliferation was measured using an MTT assay (methylthiazol tetrazolium assay)
[81]. Briefly, monolayers of 2  104 ECs were exposed to standard medium (M199, Sigma,
USA) supplemented with 20% serum taken before and after CR for 24 h in hypoxic
condition (1% O2). After the exposition, cells were incubated in a medium containing
1.25 mg/ml of the MTT salt (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bro-
mide) for 4 h at 37C. The active mitochondrial dehydrogenases metabolized the conver-
sion of MTT salt [82]. The generated formazan product was dissolved with the acidic
solution of sodium dodecyl sulfate and N,N-dimethylformamide. Absorbance of the
converted dye was recorded at 595 nm with a reference wavelength of 690 nm.
• Migration and invasionwere tested using Boyden chamber (Cultrex Kit, USA). Briefly, ECswere
grown to 80% confluency in a culture medium. Then the cells were harvested, resuspended in
serum-freemedium and place in an uppermigration chamber (5 104 cell/100 μl). To detect cell
migration, this chamber was coated only with assay buffer in the contrary to invasion
process where this surface was coated with basement membrane extracts. Cells were then
stimulated for 24 h in hypoxic condition (1% O2) with standard medium supplemented
with 20% serum taken before and after CR placed in the lower chamber. Migrated cells
were detached and treated with calcein AM in the lysis buffer. Fluorescence of cell lysates
was measured using 480 and 520 nm wavelengths for excitation and emission, respec-
tively.
• Generation of ROS by endothelial cells treated with standard medium supplemented with
20% serum taken before and after CR for 24 h was assessed by labeling with 20,70-
dichlorodihydrofluorescein diacetate (H2DCFDA, Molecular Probes, USA) that is trapped
inside the cells and activated by intracellular ROS. Briefly, following the exposure to
medium, 2  104 cells were loaded with 10 μM H2DCFDA for 30 min and then treated
with the lysis buffer. Fluorescence emitted by cell lysates was measured using wave-
lengths of 485 and 535 nm for excitation and emission, respectively [83].
• To detect serum factors we used the immunoassays from R&D Systems (USA).
• Nitric oxide and TAS were measured by colorimetric assays from R&D Systems (USA)
and Cayman (USA), respectively.
• SOD and catalase were tested using enzymatic tests from Cayman (USA).
• Fat content was estimated by bioelectrical impedance analysis (Tanita/Acern, Japan).
• Homeostasis model assessment (HOMA-IR)—an index of insulin resistance was measure
using the following equation: fasting insulinemia (mU/ml) fasting glycemiamg/dl)/405 [84].
5.4. Statistical analysis
Statistical analysis was performed using GraphPad Prism™ 6.00 (GraphPad Software Inc., San
Diego, California). The Wilcoxon test and the Mann-Whitney test were used for comparing
paired and unpaired data, respectively. The data were also analyzed with repeated measures
analysis of variance using a post hoc test for multiple comparisons. Associations between
variables were assessed with the Spearman correlation. The level of significance was set at
p < 0.05.




Moderate CR induced a reduction of the anthropometric measurements and angiogenic
adipokines in all subjects (leptin, II-6 and TNF-α) (Figure 7A and B). The largest decrease was
achieved in TNF-α concentration in normoglycemic obese patients (N: 66  5% vs. GI:
38 7%) Similarly, a decrease in fat mass was greater in obese patients with a normal glucose
profile (N: 10.4  2.1% vs. GI: 8.7  3.3%). CR also decreased the percentage of patients
with life-threatening obesity from 34 to 18%. Actually, more beneficial changes in lipids and
carbohydrates parameters were observed in normoglycemic obese subjects (HOMA-IR: N:
27  4% vs. GI: 8  2%; cholesterol: N: 9  5% vs. GI: 1.5  1%; triglycerides: N:
24  9% vs. GI: 7  4%). CR was less effective in the obese with GI, certainly because of a
higher percentage of patients with life-threatening obesity (GI: 52% vs. N: 34%). Dietary
treatment significantly reduced the pro-angiogenic (VEGF: 11  6%, bFGF: 35  10%,
Ang-1: 18  9%) and angiostatic (endostatin: 126  5%, IP-10: 76  14%, IFN-gamma:
74  17%) factors, especially in normoglycemic patients (Figure 7A and B). In the obese with
GI, CR reduced only two angiogenic parameters of 13 analyzed (angiostatin-1: 27  7%,
endostatin: 8  2%). This group was also characterized by a higher concentration of VEGF
(+105  12%), IFN-gamma (+225  24%), IP-10 (+103  25%) and lower IGF-1 (49  15%)
after the treatment when compared to the normoglycemic obese. It should be emphasized that,
at baseline, the GI group was characterized by a higher concentration of VEGF (+93  18%)
and lower IP-10 (45  13%). Additionally, the decrease in pro-angiogenic leptin and bFGF
was positively correlated with the reduction of anthropometric measurements (body mass,
BMI, WC (waist circumference) and fat mass) after dietary intervention. CR in both tested
groups, in a comparable way, reduced pro-inflammatory markers of endothelial activation
(sICAM-1 in both groups 5  1.5%; sE-selectin: N: 21  4% vs. GI: 42  10%) and ADMA
(N: 35  5% vs. GI: 37  10%), but did not change the production of NO (Figure 7A and B).
The changes in coagulation and fibrinolisis parameters were far less pronounced especially in
obese patients with GI. Mild CR was only partially effective in reducing oxidative stress by
increasing SOD in obese normoglycemic patients. The culture medium supplemented with
serum obtained from obese patients, before and after CR, modified endothelial function essen-
tial for angiogenesis. We have documented an increase in endothelial proliferation and a
decrease in endothelial migration and invasion after 8 weeks of CR under hypoxic condition.
These observations were less pronounced in the obese with GI (Figure 7A and B).
5.6. Discussion
Eight weeks of moderate CR reduced the anthropometric measurements (BMI, body weight
and fat mass), pro-angiogenic and pro-inflammatory adipokines such leptin, Il-6 and TNF-α in
all obese patients. Additionally, in both tested groups (i.e. in normoglycemic and in glucose
intolerance participants), CR in a comparable way, reduced pro-inflammatory markers of
endothelial activation (sICAM-1 and sE-selectin), inhibitor of eNOS—ADMA, but did not
change the production of NO. Worth emphasizing is that more beneficial changes were
observed in normoglycemic obese. We have observed: (i) the improvement of laboratory tests
assessing carbohydrate and lipid profile (especially HOMA), (ii) reduced level of many angio-
genic and angiostatic factors and (iii) modification of angiogenic properties of EC. Moderate
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Figure 7. Effect of moderate caloric restriction in (A) obese normoglycemic patients, (B) obese patients with glucose
intolerance. Abbreviations: IR, insulin resistance; Il-6, interleukin 6; TNF-alpha, tumor necrosis factor-alpha; sICAM-1,
soluble form of intercellular cell adhesion molecule-1; sVCAM-1, soluble form of vascular cell adhesion molecule-1; sE-
selectin, soluble form of selectin E; TM, thrombomodulin; vWF, von Wilebrand factor; PAI-1, plasminogen activator
inhibitor-1; ADMA, asymmetric dimethylarginine; NO, nitric oxide; VEGF, vascular endothelial growth factor; bFGF,
basic fibroblast growth factor; Ang-1, angiopoetin 1; IGF-1, insulin-like growth factor 1; Il-8, interleukin 8; MMP,
metalloproteinase; Ang-2, angiopoetin 2; TBS-1, thrombospondin-1; TIMP, tissue inhibitor of metalloproteinase; INF-γ,
interferon γ; IP-10, interferon-inducible protein;$, without changes.
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CR has probably not exerted as many beneficial effects in the obese patients with GI because
this group was characterized by a greater number of patients with life-threatening obesity. The
parameters of oxidative stress were the least susceptible for modification by moderate CR.
Additionally, we have documented a positive correlation with the reduction of all tested
anthropometric measurements after dietary intervention and a decrease in pro-angiogenic
leptin and bFGF.
Weight reduction in obese people is not easy to achieve due to the difficulty in maintaining a
dietary regimen and the usual co-existence of IR. Insulin resistance makes it harder for patients
to lose unnecessary body weight by hindering glucose utilization by the muscles and liver [85].
There is no doubt that CR improves endothelial function [7–9, 68], particularly the concentra-
tion of adhesive molecules, pro-inflammatory cytokines and NO production [7, 8, 66]. It is well
documented that changes in NO production by endothelium is triggered by diet are generally
related to changes in weight loss [7, 8, 67], plasma glucose concentration [68] and duration of
CR [86]. However, a short-term dietary intervention does not always improve vascular
endothelial-derived NO response [87, 88]. The parameters involved in coagulation and fibri-
nolysis are less prone to modification [7, 66, 67].
An important issue is whether even a small degree of CR, resulting in a modest loss of body
weight, will improve endothelial function. To investigate this, it is necessary to find a param-
eter that is sensitive enough to reflect an improvement of endothelial function even with only a
slight weight loss. Using ECs cultured in vitro in medium supplemented with serum taken
from the obese patients before and after CR, we found a correlation between EC proliferation
and weight loss after CR. This effect was especially apparent in male subjects [78]. The
mechanisms underlying changes in EC angiogenic properties in response to dietary interven-
tion are difficult to define unequivocally. They are probably context-dependent. In addition to
the effects exerted by leptin and adiponectin through their similar receptors [59] and the effect
of sex hormones [89, 90], changes in EC metabolism may be exerted by the alteration of energy
homeostasis [91, 92]. Various metabolic pathways are now recognized as contributing signifi-
cantly to obesity-associated angiogenesis [93, 94]. Proliferation is an energy-consuming pro-
cess, it is tempting to hypothesize that the magnitude of serum-induced endothelial growth
response reflects a tendency for conserving energy during CR. Interesting observations have
recently been published by Reinhardt et al. [91, 92]. They observed that patients with a
“thrifty” phenotype (economic and energy saving) could distribute more energy for cell pro-
liferation and lose less weight during CR, while patients with a “spendthrift” phenotype
(wasteful and energy spending) would spend less energy for the cell proliferation and lost
more weight after CR [91]. Accordingly, we observed that individuals who had lost more
weight exhibited a decrease in cell proliferation (for quantitative data see [78]). We
documented that a moderate CR in obese subjects changes the endothelial genes expression
profile involved in the cell cycle [78]. Similarly, Ellsworth et al. have recently revealed signifi-
cant changes in peripheral blood gene expression patterns, including those involved in cell
cycle in obese patients undergoing intensive long-term lifestyle modifications. Observed
changes occurred only in patients who achieved considerable weight loss (>10%) over 1 year,
but not in participants with minimal weight loss [65]. As the authors emphasized, the mecha-
nism by which a CR protects the function of capillaries remains unexplained. It certainly
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improves many of the endothelial functions essential for angiogenesis, such as proliferation,
tube formation and prevents against apoptosis and aging [74], Csiszar et al. explained that the
reduction of oxidative stress and inflammation would primarily improve EC functions. Dietary
intervention drives a change in the concentration of many neuroendocrine factors, which reach
the capillary ECs from the bloodstream and initiate a variety of cytoprotective processes [77].
We have measured 13 factors involved in angiogenesis (angiogenic/angiostatic). Reducing AT
after the dietary treatment makes it less demanding for the factors necessary for angiogenesis.
Dietary restriction led to a decrease in the concentration of three pro-angiogenic factors (VEGF,
bFGF and Ang-1) and three angiostatic factors (endostatin, IP-10 and IFN-γ) in normoglycemic
obese subjects. In obese patients with GI, CR reduced only 2 parameters involved in the
angiogenesis process, out of 13 analyzed (Ang-1, endostatin). Glucose intolerance in obese
people adversely affects the angiogenesis process. This has been confirmed by Nathan et al.
where the lower adhesion, migration and tubular structure formation in endothelium were
observed compared to the normoglycemic control group [95].
One of the most important factors in the angiogenesis process that stimulates migration and
EC proliferation is VEGF [29]. Miyazawa-Hoshimoto et al. have demonstrated a positive
correlation between serum VEGF levels and anthropometric parameters of obese persons,
which indicates that visceral fat is the most important factor that determines the VEGF con-
centration in obesity. We have also observed that obese patients with high BMI and fat mass
(particularly obese with GI) exhibit elevated VEGF level at baseline when compared with
normoglycemic obese; nevertheless, CR did not reduce the level of VEGF. Weight reduction
might decrease VEGF concentration [96], however, this effect is not always achieved [52, 75,
97]. We have observed a decline in VEGF level only in the normoglycemic obese. Higher VEGF
level is characteristic for the obese with GI when compared with the normoglycemic patients
[52, 98]. Insulin stimulates VEGF production in vascular ECs [99] and in adipocytes [100]
by stimulating the HIF-1α expression [29]. The authors emphasize that insulin is a potent
mitogen, and its stimulatory effect on VEGF production and proliferation is already present
at physiological concentrations [29, 100]. EC proliferation after CR was higher in the
normoglycemic obese and was not observed in patients with GI despite significantly higher
insulin and VEGF concentrations. Severe obese patients with glucose intolerance treated with
metformin and/or moderate CR not always reduced insulin concentration and HOMA levels
[101, 102]. EC proliferation in obese subjects is complex and cannot be explained by the effects
of typical angiogenic factors as elevated level of insulin and VEGF [78]. Yamagishi et al.
performed an experiment showing that, despite higher VEGF level following insulin stimula-
tion, no increase in VEGF receptor-mediated EC proliferation was observed. They concluded
that this effect may hamper the response to pro-angiogenic VEGF in patients with
hyperinsulinemia [99]. Recent work by Aplin and Nicosia also confirms the decline in expres-
sion of VEGF receptors in the EC under hypoxia [30]. Experiment done by Csiszar et al. using
nonhuman primateMacaca mulatta after 10 years of CR showed similar observation [74].
bFGF is the subsequent crucial angiogenic factor modified by weight loss [78, 96]. The correla-
tion between bFGF and abdominal obesity is obscure [40, 41], nevertheless we observed a
positive correlation between the decrease in bFGF and the reduction in body mass, fat mass,
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BMI and waist circumference. bFGF changes endothelial angiogenic properties [38]. The corre-
lation between bFGF and MMPs in an endothelial culture medium suggests that the expres-
sion of MMPs is critical for the migration and invasiveness of cells in the formation of new
blood vessels [39]. The significant lowering of bFGF in patients treated with a diet alone was
probably one of the most important factors that contributed to the decreased migration and
invasiveness of EC after the intervention.
Endostatin inhibits the proliferation, migration, adhesion and ability to form the tubes by
altering the action of VEGF and bFGF. It blocks multiple signaling pathways (TNF-α, NF-κB,
adhesion and clotting) [47]. The elevated endostatin concentrations are characteristic of over-
weight patients [37]. Eight weeks of moderate CR was enough to decrease endostatin concen-
tration in both obese groups. It is worth to emphasize that endostatin was the only angiostatic
parameter modified by CR in obese patients with GI.
Ang-1 and Ang-2 control the maturation and stabilization of blood vessels [42, 48] and by that
means regulate AT growth [48]. Dietary restrictions reduce their concentration [75]. Ang-1 was
the only angiogenic parameter that was reduced in obese patients with GI. Since Ang-1
stimulates proliferation and migration, its reduced concentration after CR could also be
responsible for diminished endothelial angiogenic function observed in vitro. Ang-2 is synthe-
sized almost exclusively by ECs cells during vascular remodeling [103]. It destabilizes the
vascular wall to facilitate the action of other pro-angiogenic factors [104]. The mechanism of
angiopoietins’ action is not fully understood. Ang-2 has dual pro- and anti-angiogenic proper-
ties. It is believed that Ang-2 acts via a Tie-2 receptor as its antagonist, when Ang-1 is not
available or acts independently without a Tie-2 receptor [105]. Higher level of Ang-2 is
observed in patients with type 2 diabetes [106] as a hyperglycemia effect [107]. It has been
suggested that elevated concentrations of Ang-2 and hyperglycemia may promote abnormal
neovascularization and endothelial dysfunction, which in turn leads to diabetic micro- and
macroangiopathy [108].
IP-10 is a chemotactic factor for T cells, produced by various cells such as monocytes, ECs,
fibroblasts, in response to IFN-γ stimulation [50]. Dalmas et al. show higher blood levels of IP-
10 in obese patients, without any differences between diabetic and non-diabetic patients [52].
The group of obese patients with GI was characterized by a lower IP-10 (45%) at baseline. CR
reduced the IP-10 concentration by 76% only in the normoglycemic obese. The 10-year follow-
up of patients with type 2 diabetes in the MONICA/KORA clinical trial suggests that the IP-10
protein is one of the risk factors for the clinical development of diabetes [109] and its concen-
tration could be lowered by CR and lifestyle modification [110].
Infiltrating of immune cells in AT is an important factor leading to inflammation and IR [6]
Interferon-γ is known to change the macrophage phenotype to more pro-inflammatory (M1)
[53]. Patients with GI had a higher IFN-γ concentration after CR. Higher fat content and stronger
stimulation by macrophage-derived IFN-γ were the important factors for higher concentrations
of pro-inflammatory adipokines after the experiment (higher TNF-α after CR). Obese individ-
uals usually have elevated IFN-γ levels, particularly patients with central obesity [54]. Diet
intervention significantly decreased IFN-γ levels in the normoglycemic obese (74%). Although
plasma concentrations of IP-10 and IFN-γ in the obese with GI after CRwere significantly higher
when compared with the normoglycemic obese, the diet did not change their concentrations. It is
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well known that hyperglycemia in diabetic patients significantly modifies the immune response,
particularly the humoral immunity [12]. Higher levels of IP-10 and IFN-γ seen in the obese with
GI, may reflect a different immune response observed in this group.
Metformin is one of the oldest commonly used oral hypoglycemic drugs, which does not affect
insulin secretion. It functions omnidirectionally on various cells [85, 111], reducing the risk of
CVD by improving blood vessels, vascular endothelium or decreasing inflammatory markers
[85]. Animal models and in vitro experiments showed the anti-angiogenic effect of metformin
and emphasized its beneficial role which goes far beyond lowering the glucose level [112, 113].
Endothelium treated with metformin alters the secretion profile of angiogenic and angiostatic
factors [112]. Moreover, metformin protects the myocardium against hypoxia. The
cardioprotective effect of metformin is the result of the reduced oxidative stress and bFGF level,
which are responsible for hypertrophy and myocardial fibrosis [111]. The ability to reduce bFGF
concentration is one of metformin’s anti-tumor activities additional to its inhibitory effect on the
migration and proliferation of both endothelial and tumor cells [112, 113]. Our obese patients
treated with CR and metformin had tendency for higher anthropometric parameters (more
patients with life-threatening obesity), additionally more patients had treated hypertension.
The angiogenic mediators and endothelial cell function were significantly less modified by
moderate CR in compare with nomoglycemic patients treated only with diet.
6. Conclusions
AT remodeling is pathologically accelerated in an obese state due to local hypoxia leading to
reduced angiogenesis, severe immune cell infiltration with subsequent pro-inflammatory
responses and additional deterioration of EC functions. It is believed that EC dysfunction in
obesity can be reduced by CR. Moderate CR reflects a real-life situation and could be optimal to
achieve an improvement in EC. Our observations suggest that a moderate CR can improve
several parameters of EC function, especially those involved in angiogenesis. It also improves
anthropometric and metabolic measurements, but does not significantly strengthen the antioxi-
dant status. The in vitro model shows how various circulating factors, induced by CR, affect the
endothelial proliferation, migration and invasiveness. This process is a result of a reduction of
inflammation and a modification of angiogenic and angiostatic factors. Additionally, in patients
with glucose intolerance, it is also caused by potential anti-angiogenic properties of metformin.
The obtained results are particularly pronounced in the normoglycemic obese, and to a lesser
extent in the obese with GI and IR, who may have an adverse impact on AT remodeling, the
cardiovascular system and might have an increased risk of obesity-associated cancer diseases.
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A. Appendix and nomenclature: Exemplary diet
Diet plan
The energy supply was set at 1500 kcal




Sandwich with egg and radishes
• 2 slice of wholemeal bread (80 g)
• 1 teaspoon of butter (5 g)
• Lettuce
Meal Hours Share of energy supply (%) Caloric value (kcal)
I breakfast 7:00–8:00 20 300
II breakfast 10:00–11:00 20 300
Lunch 13:00–14:00 10 150
Snack 16:00–17:00 30 450
Dinner 18:30–19:30 20 300
• 1 wholemeal roll (80 g)
• 1 small tomato
• Cottage cheese (50 g)
• Fresh basil
• 2 teaspoons of olive oil (10 g)
• Black pepper
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• 1 boiled egg
• A few radishes
Tomato juice—small bottle (300 ml)
Lunch—440 kcal
Italian spaghetti—1 portion
Spaghetti should be boiled al dente.
Snack—160 kcal
Natural yogurt—2% fat (180–200 g) with 1 spoon of wheat bran.
Tangerines (2 medium size—150 g)
Dinner—290 kcal
Tuna salad with parsley sauce (1 portion)
1 slice of wholemeal bread (40 g)
• Rucola salad
• 100 g cocktail tomatoes
• 1/3 red pepper
• Canned tuna in its own sauce (50 g—2 spoons)
• Natural yogurt 2% fat (75 g—3 spoons)
Ingredients for 3 potions:
• 250 g wholemeal pasta
• 1 cane of tomatoes or fresh tomatoes
• 1 chicken breast (200 g)
• 10 capers
• 10 black olives
• 1 small onion
• 2 cloves of garlic
• Olive oil (1 spoon)
• Fresh parsley (2 spoons)
• Pepper, basil
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• Sunflower seeds (15 g—3 teaspoons)
• Parsley
• Lemon juice
Exemplary menu 1500 kcal—version 2
I breakfast—330 kcal.
Sandwich with ham and vegetables
• 1 slice of ray bred (40 g)
• Butter (1 teaspoon)
• Lettuce
• 1 slice of chicken ham (20 g)
• Small tomato (100 g)
• 1–2 small cucumbers
Natural yogurt 2% fat (400 g)
II breakfast—280 kcal
Cottage cheese
• Cottage cheese—3% fat (150 g)
• A few radishes (chopped or grated)
• Sunflower seeds (1 spoon)
1 slice of ray bread (40 g)
Lunch—440 kcal.
Asparagus cream soup—1 portion
Ingredients for 4 portions
• 1 bunch of green asparagus
• 1 zucchini
• 1 clove of garlic
• 1 onion
• 1 liter of bullion
• Olive oil (2 spoons)
• Pepper
• 1–2 teaspoons of lemon juice
• pine nuts/ almond flakes (4 teaspoons)
• cream cheese or natural yoghurt (4 teaspoons)
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1 wholemeal roll (80 g) or 2 slices of rye bread with butter (1 teaspoon)
1 orange (350 g) or ½ pomelo
Snack—160 kcal
Oatmeal with dried plums (49 g)
Dinner—290 kcal
Salad with baked pepper and tomatoes
• 1 green or yellow pepper baked in the oven and peeled
• 1 big tomato (200 g)
• 1 spoon of olive oil or sunflower oil
• 1 spoon of chopped lettuce
• 1 spoon of chopped celery leaves
• Pepper
Sandwich with ham
• 1 slice of ray bread (40 g)
• 2 slices of chicken ham (40 g)
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